1. Baron EP. Comprehensive review of medicinal marijuana, cannabinoids, and therapeutic implications in medicine and headache: What a long strange trip it’s been … Headache. 2015 Jun;55(6):885–916. doi: 10.1111/head.12570. [PubMed] [CrossRef] [Google Scholar]

2. Schluttenhofer C, Yuan L. Challenges towards revitalizing hemp: A multifaceted crop. Trends Plant Sci. 2017 Nov;22(11):917–29. doi: 10.1016/j.tplants.2017.08.004. [PubMed] [CrossRef] [Google Scholar]

3. Andre CM, Hausman JF, Guerriero G. Cannabis sativa: The plant of the thousand and one molecules. Front Plant Sci. 2016 Feb 4;7:19. doi: 10.3389/fpls.2016.00019. [PMC free article] [PubMed] [CrossRef] [Google Scholar]

4. Zlebnik NE, Cheer JF. Beyond the CB1 receptor: Is cannabidiol the answer for disorders of motivation? Annu Rev Neurosci. 2016 Jul 8;39:1–17. doi: 10.1146/annurev-neuro-070815-014038. [PMC free article] [PubMed] [CrossRef] [Google Scholar]

5. Devinsky O, Cilio MR, Cross H, et al. Cannabidiol: Pharmacology and potential therapeutic role in epilepsy and other neuropsychiatric disorders. Epilepsia. 2014 Jun;55(6):791–802. doi: 10.1111/epi.12631. [PMC free article] [PubMed] [CrossRef] [Google Scholar]

6. Bostwick JM. Blurred boundaries: The therapeutics and politics of medical marijuana. Mayo Clin Proc. 2012 Feb;87(2):172–86. doi: 10.1016/j.mayocp.2011.10.003. [PMC free article] [PubMed] [CrossRef] [Google Scholar]

7. Legal recreational marijuana states and DC: Cannabis laws with possession and cultivation limits [Internet] Santa Monica, CA: ProCon.org; 2018. Jun 27, [cited 2018 Aug 23]. Available from: https://marijuana.procon.org/view.resource.php?resourceID=006868. [Google Scholar]

8. Abrams DI, Jay CA, Shade SB, et al. Cannabis in painful HIV-associated sensory neuropathy: A randomized placebo-controlled trial. Neurology. 2007 Feb 13;68(7):515–21. doi: 10.1212/01.wnl.0000253187.66183.9c. [PubMed] [CrossRef] [Google Scholar]

9. Devinsky O, Cross JH, Laux L, et al. Cannabidiol in Dravet Syndrome Study Group. Trial of cannabidiol for drug-resistant seizures in the Dravet syndrome. N Engl J Med. 2017 May 25;376(21):2011–20. doi: 10.1056/NEJMoa1611618. [PubMed] [CrossRef] [Google Scholar]

10. Fuss J, Steinle J, Bindila L, et al. A runner’s high depends on cannabinoid receptors in mice. Proc Natl Acad Sci U S A. 2015 Oct 20;112(42):13105–8. doi: 10.1073/pnas.1514996112. [PMC free article] [PubMed] [CrossRef] [Google Scholar]

11. Zanelati TV, Biojone C, Moreira FA, Guimarães FS, Joca SR. Antidepressant-like effects of cannabidiol in mice: Possible involvement of 5-HT1A receptors. Br J Pharmacol. 2010 Jan;159(1):122–8. doi: 10.1111/j.1476-5381.2009.00521.x. [PMC free article] [PubMed] [CrossRef] [Google Scholar]

12. Zuardi AW, Rodrigues NP, Silva AL, et al. Inverted U-shaped dose-response curve of the anxiolytic effect of cannabidiol during public speaking in real life. Front Pharmacol. 2017 May 11;8:259. doi: 10.3389/fphar.2017.00259. [PMC free article] [PubMed] [CrossRef] [Google Scholar]

13. Bergamaschi MM, Queiroz RH, Chagas MH, et al. Cannabidiol reduces the anxiety induced by simulated public speaking in treatment-naïve social phobia patients. Neuropsychopharmacology. 2011 May;36(6):1219–26. doi: 10.1038/npp.2011.6. [PMC free article] [PubMed] [CrossRef] [Google Scholar]

14. Zuardi AW, Cosme RA, Graeff FG, Guimarães FS. Effects of ipsapirone andcannabidiol on human experimental anxiety. J Psychopharmacol. 1993 Jan;7(1 Suppl):82–8. doi: 10.1177/026988119300700112. [PubMed] [CrossRef] [Google Scholar]

15. Guimarães FS, Chiaretti TM, Graeff FG, Zuardi AW. Antianxiety effect of cannabidiol in the elevated plus-maze. Psychopharmacology (Berl) 1990;100(4):558–9. doi: 10.1007/bf02244012. [PubMed] [CrossRef] [Google Scholar]

16. Zhornitsky S, Potvin S. Cannabidiol in humans—the quest for therapeutic targets. Pharmaceuticals (Basel) 2012 May 21;5(5):529–52. doi: 10.3390/ph5050529. [PMC free article] [PubMed] [CrossRef] [Google Scholar]

17. Zuardi AW, Guimarães FS, Moreira AC. Effect of cannabidiol on plasma prolactin, growth hormone and cortisol in human volunteers. Braz J Med Biol Res. 1993 Feb;26(2):213–7. [PubMed] [Google Scholar]

18. Iffland K, Grotenhermen F. An update on safety and side effects of cannabidiol: A review of clinical data and relevant animal studies. Cannabis Cannabinoid Res. 2017 Jun 1;2(1):139–54. doi: 10.1089/can.2016.0034. [PMC free article] [PubMed] [CrossRef] [Google Scholar]

19. Collen M. Prescribing cannabis for harm reduction. Harm Reduct J. 2012 Jan 1;9:1. doi: 10.1186/1477-7517-9-1. [PMC free article] [PubMed] [CrossRef] [Google Scholar]

20. Loflin MJE, Earleywine M, Farmer S, Slavin M, Luba R, Bonn-Miller M.Placebo effects of edible cannabis: Reported intoxication effects at a 30-minute delay J Psychoactive Drugs 2017November–December495393–7. 10.1080/02791072.2017.1354409 [PubMed] [CrossRef] [Google Scholar]

21. State laws [Internet] Washington, DC: NORML Foundation; c2018. [cited 2018 Aug 7]. Available from: https://norml.org/laws. [Google Scholar]

22. Mitchell T. Did the DEA just quietly approve CBD? [Internet] Denver, CO: Westword; 2018. Jun 2, [cited 2018 Aug 7] Available from: www.westword.com/marijuana/dea-quietly-gives-cbd-other-non-psychoactive-cannabinoids-the-go-ahead-10377016. [Google Scholar]

23. Clarification of the new drug code (7350) for marijuana extract [Internet] Springfield, VA: Drug Enforcement Administration, Diversion Control Division; 2017. [cited 2018 Aug 7]. Available from: www.deadiversion.usdoj.gov/schedules/marijuana/m_extract_7350.rtfl. [Google Scholar]

24. Steinmetz K. What marijuana legalization in Canada could mean for the United States [Internet] New York, NY: Time; 2017. Apr 6, [cited 2018 Aug 7]. Available from: http://time.com/4728091/canada-legalizing-marijuana-united-states-weed-pot/ [Google Scholar]


Leave a Reply

Your email address will not be published. Required fields are marked *